Two Sigma Securities’s Esperion Therapeutics ESPR Stock Holding History

Two Sigma Securities’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-27,909	Closed	-$76.5K	–	1917
2026 Q1	$76.5K	Buy	+27,909	New	+$88.4K	0.01%	1209
2025 Q4	–	Sell	-13,077	Closed	-$34.7K	–	1625
2025 Q3	$34.7K	Buy	+13,077	New	+$25.3K	0.01%	1044
2023 Q4	–	Sell	-36,678	Closed	-$35.9K	–	3175
2023 Q3	$35.9K	Buy	+36,678	New	+$53.1K	﹤0.01%	2508
2023 Q2	–	Sell	-11,792	Closed	-$18.7K	–	2927
2023 Q1	$18.7K	Buy	+11,792	New	+$60.9K	﹤0.01%	2372
2018 Q2	–	Sell	-3,940	Closed	-$285K	–	2726
2018 Q1	$285K	Sell	3,940 -1,251	-24%	-$91.9K	﹤0.01%	2039
2017 Q4	$342K	Buy	+5,191	New	+$279K	0.01%	917
2017 Q3	–	Sell	-6,857	Closed	-$317K	–	992
2017 Q2	$317K	Buy	+6,857	New	+$252K	0.06%	337

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Two Sigma Securities's ESPR Position: Q2 2026 in Review

Two Sigma Securities sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 27,909 shares — an estimated $76.5K sold.

Two Sigma Securities first reported a position in ESPR in Q2 2017 and held it in 7 quarters. The position peaked at $342K in Q4 2017. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Two Sigma Securities reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Two Sigma Securities sold 27,909 Esperion Therapeutics shares in Q2 2026, an estimated $76.5K.
Two Sigma Securities first reported a position in Esperion Therapeutics in Q2 2017 and held it in 7 quarters.
Two Sigma Securities's Esperion Therapeutics position peaked at $342K in Q4 2017.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.